Article Correctness Is Author's Responsibility: A New Era of Care: The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center to Open in January 2020

Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next …

read more

Article Correctness Is Author's Responsibility: Claus Torp Jensen Has Been Appointed First Chief Digital Officer and Head of Technology for Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology. His recruitment follows an expansive national search to identify a leader wi…

read more

Article Correctness Is Author's Responsibility: Memorial Sloan Kettering Among the Top “Best Hospitals” for Cancer Care and Ranked First in Gynecology by U.S News & World Report

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK …

read more

Article Correctness Is Author's Responsibility: Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to hi…

read more

Article Correctness Is Author's Responsibility: Pivotal Results from Phase III Trial Show That the Combination of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo(r)) and ipilimumab (Yervoy(r)) significantly increased overall survival versus treatment with sunitinib (Sutent(r)) alone, according…

read more